Skip to main content
Erschienen in:

11.09.2018 | Originalien

Neuroendokrines Prostatakarzinom

verfasst von: PD Dr. S. Tritschler, R. Erdelkamp, C. Stief, M. Hentrich

Erschienen in: Journal für Urologie und Urogynäkologie/Österreich | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Neuroendokrine Prostatakarzinome (NEPC) treten zumeist in Form eines gemischt neuroendokrin-azinären Prostatakarzinoms auf, das sich unter antiandrogener Therapie entwickelt (t-NEPC). Etwa 30–40 % aller metastasierten kastrationsresistenten Prostatakarzinome weisen neuroendokrine Anteile auf. Primäre kleinzellige Prostatakarzinome sind hingegen äußerst selten. Ein t‑NEPC sollte in Betracht gezogen werden, wenn trotz rascher Progression ein disproportional niedriger PSA(prostataspezifisches Antigen)-Wert vorliegt und neuroendokrine Marker wie Chromogranin A oder neuronenspezifische Enolase erhöht sind. Hierbei korreliert das Risiko für die Entwicklung eines t‑NEPC mit dem initialen Gleason-Score. Die Therapie orientiert sich an der Behandlung kleinzelliger Bronchialkarzinome. Bei negativem PSA ist eine Chemotherapie mit Cisplatin und Etoposid Therapie der Wahl, worunter Ansprechraten von 30–60 % mit einem medianen Überleben von meist unter einem Jahr erreicht werden können. Bei deutlich erhöhtem PSA sollte eine Chemotherapie mit Carboplatin und Docetaxel erwogen werden.
Literatur
1.
Zurück zum Zitat Parimi V, Goyal R, Poropatich K et al (2014) Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2:273–285PubMedPubMedCentral Parimi V, Goyal R, Poropatich K et al (2014) Neuroendocrine differentiation of prostate cancer: a review. Am J Clin Exp Urol 2:273–285PubMedPubMedCentral
2.
Zurück zum Zitat Asmis TR, Reaume MN, Dahrouge S et al (2006) Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int 97:711–715CrossRefPubMed Asmis TR, Reaume MN, Dahrouge S et al (2006) Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int 97:711–715CrossRefPubMed
4.
Zurück zum Zitat Small Ej HJ, Youngren J et al (2015) Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resitant to abiraterone (Abi) or enzaltuamid (Enz): preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). J Clin Oncol 33:abstr 5003CrossRef Small Ej HJ, Youngren J et al (2015) Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resitant to abiraterone (Abi) or enzaltuamid (Enz): preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). J Clin Oncol 33:abstr 5003CrossRef
5.
Zurück zum Zitat Berruti A, Mosca A, Porpiglia F et al (2007) Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 178:838–843 (quiz 1129)CrossRefPubMed Berruti A, Mosca A, Porpiglia F et al (2007) Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 178:838–843 (quiz 1129)CrossRefPubMed
6.
Zurück zum Zitat Hirano D, Okada Y, Minei S et al (2004) Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45:586–592 (discussion 592)CrossRefPubMed Hirano D, Okada Y, Minei S et al (2004) Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 45:586–592 (discussion 592)CrossRefPubMed
7.
Zurück zum Zitat Alanee S, Moore A, Nutt M et al (2015) Contemporary incidence and mortality rates of neuroendocrine prostate cancer. Anticancer Res 35:4145–4150PubMed Alanee S, Moore A, Nutt M et al (2015) Contemporary incidence and mortality rates of neuroendocrine prostate cancer. Anticancer Res 35:4145–4150PubMed
8.
Zurück zum Zitat Beltran H, Prandi D, Mosquera JM et al (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298–305CrossRefPubMedPubMedCentral Beltran H, Prandi D, Mosquera JM et al (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298–305CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Aggarwal RR, Feng FY, Small EJ (2017) Emerging categories of disease in advanced prostate cancer and their therapeutic implications. Oncology 31:467–474PubMed Aggarwal RR, Feng FY, Small EJ (2017) Emerging categories of disease in advanced prostate cancer and their therapeutic implications. Oncology 31:467–474PubMed
10.
Zurück zum Zitat Epstein JI, Amin MB, Beltran H et al (2014) Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756–767CrossRefPubMedPubMedCentral Epstein JI, Amin MB, Beltran H et al (2014) Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756–767CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Tamas EF, Epstein JI (2006) Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol 30:980–985CrossRefPubMed Tamas EF, Epstein JI (2006) Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol 30:980–985CrossRefPubMed
12.
Zurück zum Zitat Marcus DM, Goodman M, Jani AB et al (2012) A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 15:283–288CrossRefPubMed Marcus DM, Goodman M, Jani AB et al (2012) A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis 15:283–288CrossRefPubMed
13.
Zurück zum Zitat Wang W, Epstein JI (2008) Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 32:65–71CrossRefPubMed Wang W, Epstein JI (2008) Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 32:65–71CrossRefPubMed
14.
Zurück zum Zitat Evans AJ, Humphrey PA, Belani J et al (2006) Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 30:684–693CrossRefPubMed Evans AJ, Humphrey PA, Belani J et al (2006) Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 30:684–693CrossRefPubMed
15.
Zurück zum Zitat Aparicio A, Tzelepi V (2014) Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. Oncology 28:831–838PubMed Aparicio A, Tzelepi V (2014) Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. Oncology 28:831–838PubMed
16.
Zurück zum Zitat Stephens PJ, Gay LM et al (2016) Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate. J Clin Oncol 34:5027CrossRef Stephens PJ, Gay LM et al (2016) Comprehensive genomic profiling of neuroendocrine carcinoma of the prostate. J Clin Oncol 34:5027CrossRef
17.
Zurück zum Zitat Santoni M, Conti A, Burattini L et al (2014) Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 1846:630–637PubMed Santoni M, Conti A, Burattini L et al (2014) Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. Biochim Biophys Acta 1846:630–637PubMed
18.
19.
Zurück zum Zitat Wang HT, Yao YH, Li BG et al (2014) Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis—a systematic review and pooled analysis. J Clin Oncol 32:3383–3390CrossRefPubMed Wang HT, Yao YH, Li BG et al (2014) Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis—a systematic review and pooled analysis. J Clin Oncol 32:3383–3390CrossRefPubMed
20.
Zurück zum Zitat Beltran H (2016) Update on the biology and management of neuroendocrine prostate cancer. Clin Adv Hematol Oncol 14:513–515PubMed Beltran H (2016) Update on the biology and management of neuroendocrine prostate cancer. Clin Adv Hematol Oncol 14:513–515PubMed
21.
Zurück zum Zitat Luboldt W, Zophel K, Wunderlich G et al (2010) Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT. Mol Imaging Biol 12:78–84CrossRefPubMed Luboldt W, Zophel K, Wunderlich G et al (2010) Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT. Mol Imaging Biol 12:78–84CrossRefPubMed
22.
Zurück zum Zitat Alonso O, Gambini JP, Lago G et al (2011) In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer. Clin Nucl Med 36:1063–1064CrossRefPubMed Alonso O, Gambini JP, Lago G et al (2011) In vivo visualization of somatostatin receptor expression with Ga-68-DOTA-TATE PET/CT in advanced metastatic prostate cancer. Clin Nucl Med 36:1063–1064CrossRefPubMed
23.
Zurück zum Zitat Gofrit ON, Frank S, Meirovitz A et al (2017) PET/CT with 68 ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancer. Clin Nucl Med 42:1–6CrossRefPubMed Gofrit ON, Frank S, Meirovitz A et al (2017) PET/CT with 68 ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancer. Clin Nucl Med 42:1–6CrossRefPubMed
25.
Zurück zum Zitat Amato RJ, Logothetis CJ, Hallinan R et al (1992) Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147:935–937CrossRefPubMed Amato RJ, Logothetis CJ, Hallinan R et al (1992) Chemotherapy for small cell carcinoma of prostatic origin. J Urol 147:935–937CrossRefPubMed
26.
Zurück zum Zitat Oesterling JE, Hauzeur CG, Farrow GM (1992) Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 147:804–807CrossRefPubMed Oesterling JE, Hauzeur CG, Farrow GM (1992) Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 147:804–807CrossRefPubMed
27.
Zurück zum Zitat Taplin ME, George DJ, Halabi S et al (2005) Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 66:386–391CrossRefPubMed Taplin ME, George DJ, Halabi S et al (2005) Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology 66:386–391CrossRefPubMed
28.
Zurück zum Zitat Aparicio AM, Harzstark AL, Corn PG et al (2013) Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19:3621–3630CrossRefPubMedPubMedCentral Aparicio AM, Harzstark AL, Corn PG et al (2013) Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19:3621–3630CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Culine S, El Demery M, Lamy PJ et al (2007) Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 178:844–848 (discussion 848)CrossRefPubMed Culine S, El Demery M, Lamy PJ et al (2007) Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 178:844–848 (discussion 848)CrossRefPubMed
30.
Zurück zum Zitat Flechon A, Pouessel D, Ferlay C et al (2011) Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 22:2476–2481CrossRefPubMed Flechon A, Pouessel D, Ferlay C et al (2011) Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 22:2476–2481CrossRefPubMed
31.
Zurück zum Zitat Papandreou CN, Daliani DD, Thall PF et al (2002) Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072–3080CrossRefPubMed Papandreou CN, Daliani DD, Thall PF et al (2002) Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 20:3072–3080CrossRefPubMed
32.
Zurück zum Zitat Tagawa ST (2014) Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. J Clin Oncol 32:3360–3364CrossRefPubMed Tagawa ST (2014) Neuroendocrine prostate cancer after hormonal therapy: knowing is half the battle. J Clin Oncol 32:3360–3364CrossRefPubMed
33.
Metadaten
Titel
Neuroendokrines Prostatakarzinom
verfasst von
PD Dr. S. Tritschler
R. Erdelkamp
C. Stief
M. Hentrich
Publikationsdatum
11.09.2018
Verlag
Springer Vienna
Erschienen in
Journal für Urologie und Urogynäkologie/Österreich / Ausgabe 3/2018
Print ISSN: 1023-6090
Elektronische ISSN: 1680-9424
DOI
https://doi.org/10.1007/s41972-018-0051-1

Weitere Artikel der Ausgabe 3/2018

Journal für Urologie und Urogynäkologie/Österreich 3/2018 Zur Ausgabe